Norway: the UKOM report and the 2023 warning

What did Norway's healthcare investigation board find about the evidence for treating minors, and what followed?

Norway’s 2023 intervention in the debate over medical transition for minors came not from a political party or a campaigning organisation, but from Ukom, the Norwegian Healthcare Investigation Board. Ukom is an independent public body established under the Act of 16 June 2017 on the Norwegian Healthcare Investigation Board. Its task is to investigate serious incidents and serious conditions in health and care services in order to improve patient safety through learning and prevention; it does not decide criminal or civil liability (Act on the Norwegian Healthcare Investigation Board, 2017).

Background

Norway’s 2023 intervention in the debate over medical transition for minors came not from a political party or a campaigning organisation, but from Ukom, the Norwegian Healthcare Investigation Board. Ukom is an independent public body established under the Act of 16 June 2017 on the Norwegian Healthcare Investigation Board. Its task is to investigate serious incidents and serious conditions in health and care services in order to improve patient safety through learning and prevention; it does not decide criminal or civil liability (Act on the Norwegian Healthcare Investigation Board, 2017).

The report, Pasientsikkerhet for barn og unge med kjønnsinkongruens, was published on 9 March 2023. Its title translates as Patient safety for children and young people with gender incongruence. The inquiry began after Ukom received two concerns in 2022 from relatives of people aged 16 to 21 who had undergone assessment or treatment. The relatives questioned whether assessment was sufficiently thorough, whether co-occurring difficulties were properly addressed, whether information about effects and adverse effects was adequate, and whether families had been appropriately involved (Ukom, 2023).

The Board did not conduct an individual disciplinary investigation into those families’ cases, nor did it issue a prohibition on treatment. It examined the wider Norwegian system: national guidance, service organisation, variation in local practice, capacity, clinical competence, consent, evidence and patient safety. This distinction matters. The report was a system-level warning, not a ruling that every intervention for every young person was unlawful or clinically inappropriate.

At the time, Norway was pursuing a decentralised model of care. The Norwegian Directorate of Health’s national guideline, published in 2020, emphasised rights, access, non-discrimination, coordination and the development of regional provision. It expressly acknowledged that the evidence base was incomplete, but did not provide detailed clinical criteria, dosage protocols or uniform requirements for assessment before medical intervention (Norwegian Directorate of Health, 2020).

What the documents say

Insufficient evidence for a changing teenage population

Ukom’s central finding was not that there was no clinical experience in this field. Rather, it found that research-based knowledge, particularly concerning hormonal and surgical gender-affirming treatment, was inadequate, and that long-term effects were largely unknown. It highlighted a particular uncertainty about the increasingly referred teenage population: the stability of gender incongruence or dysphoria over time was not known sufficiently well for that group (Ukom, 2023).

The Board identified unanswered questions about both puberty-delaying treatment and cross-sex hormones, including safety and longer-term effects. It noted possible lifelong consequences, including effects on skeletal health and fertility, and stated that these uncertainties must be weighed against the potential benefit for those who may need treatment. The report did not claim that all treatment is harmful, or that no young person benefits. Its conclusion was that the available evidence did not adequately establish safety and effectiveness for the population then presenting to services.

Ukom also distinguished between interventions. It concentrated its patient-safety assessment on treatments it regarded as invasive and potentially associated with substantial harm: puberty blockers, gender-affirming hormones and surgery. It did not place supportive conversations, help with daily coping, prostheses or hair removal in the same risk category (Ukom, 2023).

A guideline judged too vague for patient safety

Ukom concluded that the 2020 national guideline was insufficiently prescriptive. In its view, it did not set specific requirements for assessment or medical indication before treatment began, and it left too much room for interpretation regarding consent and parental involvement. The result, Ukom said, was undesirable variation in assessment, treatment and follow-up across the country, creating risks of under-treatment, over-treatment and wrong treatment (Ukom, 2023).

The Board also argued that Norway’s existing guideline had an unusual origin. It was framed substantially around equality, access and rights following concerns about discrimination and inadequate provision for people with gender incongruence. Ukom did not say those concerns were unimportant. It said that departing from the usual process of developing an evidence-based clinical guideline had left professionals with unclear standards and patients with expectations that services could not reliably meet.

The three recommendations

Ukom made three main recommendations. First, it asked the Ministry of Health and Care Services to commission the Norwegian Directorate of Health to revise the national guideline on the basis of a systematic evidence review. Secondly, it recommended that puberty blockers and hormonal and surgical gender-affirming treatment for children and young people should be defined as utprøvende behandling: investigational treatment. Thirdly, it recommended considering a national medical quality register so that treatment, outcomes and adverse effects could be systematically recorded and studied (Ukom, 2023).

In Norwegian health policy, the label “investigational” is consequential. Ukom explained that it should bring stronger requirements for information, careful assessment, delivery and close follow-up, alongside systematic data collection for research and quality assurance. It is therefore inaccurate to present the recommendation as a simple semantic change. Equally, it is inaccurate to describe the report as itself having imposed an immediate legal ban.

The positions

The patient-safety position is that an intervention with potentially irreversible or lifelong effects should meet a correspondingly high evidential and ethical threshold, especially when offered to minors whose physical, psychological, sexual and social development is ongoing. Ukom’s approach was that uncertainty should produce stronger safeguards, more comprehensive assessment, clearer consent procedures and outcomes monitoring, rather than routine expansion of medical pathways.

The affirmative-care position is different. Norway’s patient organisation PKI Norge, alongside FRI and Skeiv Ungdom, criticised the report’s evidence appraisal, its framing of the concerns that triggered the inquiry and its proposed investigational classification. They argued that such a classification could reduce young people’s access to necessary healthcare, potentially make research participation the practical route to treatment, and conflict with positions taken by international medical associations (PKI Norge, 2023).

Both positions identify genuine risks. Ukom was concerned about medical decisions being made in conditions of weak evidence and uneven practice. Its critics were concerned that restriction, delay and uncertainty in services could worsen distress, exclusion and self-medication. The policy question is not whether vulnerable young people deserve care. It is what form of care can credibly be described as safe, evidence-based and proportionate when the evidence on medical outcomes remains incomplete.

Interpretation

Beyond Gender’s reading is that the UKOM report is important because it records, in the language of patient safety rather than political controversy, a basic clinical problem: Norway’s system was being asked to deliver high-stakes interventions to minors without an adequate evidence base, consistent national assessment standards or robust long-term outcome data. The Board’s warning was particularly significant because it did not come from outside the healthcare system. It came from Norway’s independent body specifically charged with investigating serious risks in health services.

The report also exposes the weakness of treating “access” as if it settles the question of medical necessity. Access to compassionate, timely and competent support is essential. But a right to healthcare does not logically create a right to a particular medical intervention when its safety and effectiveness for a specific patient group have not been sufficiently established. Ukom’s recommendation for investigational status recognised this distinction.

What followed was partial movement rather than a decisive national settlement. In a 2023 parliamentary answer, Health Minister Ingvild Kjerkol said the Ministry was considering Ukom’s recommendations with the regional health authorities, while the Directorate planned dialogue with professional and user groups on whether to adjust the guideline (Stortinget, 2023). In 2024, Helse Sør-Øst asked Oslo University Hospital to assess how investigational medical treatment for under-18s could be conducted through a clinical treatment study. The hospital stated that the study framework had not been decided and that puberty blockers, testosterone and oestrogen remained available through the National Treatment Service for Gender Incongruence (Oslo University Hospital, 2024).

As of 10 September 2026, the Directorate’s public page still recorded 9 June 2021 as the last professional amendment to the national guideline. That does not demonstrate that nothing has changed in practice, but it does show that Ukom’s requested evidence-based national revision had not appeared on that page as a completed replacement guideline (Norwegian Directorate of Health, 2020).

Open questions

Norway has yet to answer several questions that the UKOM report made unavoidable. Has a systematic evidence review been completed for puberty blockers, testosterone, oestrogen and surgery in under-18s? What clinical criteria, if any, are now nationally required before treatment? How are co-occurring mental-health conditions, autism, trauma, sexuality, safeguarding and family circumstances assessed in practice? And what outcomes are being recorded over years rather than months?

There is also a governance question. If treatment remains available while a clinical-study model is being explored, what exactly are the clinical and legal safeguards in the interim? Families, clinicians and young people need transparent answers, not broad assurances. A national quality register, as recommended by Ukom, would not by itself resolve the ethical dispute. It would, however, make it harder for any side to rely on assumption where long-term evidence should be.

On the European timeline

Episodes on this subject

Child Services Stole My Child and Transitioned Her! | Ellie

The End of the Gay Rights Revolution? | Ronan McCrea